| Accession |
PRJCA023526 |
| Title |
A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects with Relapsed or Refractory Multiple Myeloma |
| Relevance |
Medical |
| Data types |
Cytogenetic FISH testing
|
| Organisms |
Homo sapiens
|
| Description |
This is a Phase 2, open-label, multicenter confirmatory study to evaluate the efficacy and safety of LCAR-B38M CAR-T cells in adult Chinese subjects with relapsed or refractory multiple myeloma. Approximately 60 subjects will be enrolled in the main cohort of the study. Enrolled subjects will undergo apheresis for peripheral blood mononuclear cells (PBMC). |
| Sample scope |
Multiisolate |
| Release date |
2024-02-07 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Janssen Research & Development, LLC
|
|
2018L02212
|
|
|
|
| Submitter |
Jian-Qing
Mi (jianqingmi@shsmu.edu.cn)
|
| Organization |
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
| Submission date |
2024-02-07 |
